Acne Patch Private Label: FDA Device Listing China Supplier Guide

A private-label acne patch sold in the US is regulated as a medical device, not a cosmetic. Your China supplier holds the manufacturing registration (or should); you, the brand, must register as a foreign or domestic establishment, list the product, and keep a 510(k)-exempt determination on file. Budget 3–5 weeks and roughly USD 5,000–7,000 in FDA fees plus supplier documentation before your first shipment clears.

The quick version: what gets filed, by whom, and when

Here is the split that trips up most first-time buyers. The factory makes the patch. You own the label. FDA treats you as the specification developer, which means the regulatory paperwork is yours, not theirs.

(And yes, the FDA fee is non-refundable even if you never ship a single carton. We've watched three brands learn that the hard way.)

That table reflects what we saw across 2025 and early 2026 orders out of our Zhongshan facility. Your numbers will vary by consultant and whether you bundle listing with a broader compliance retainer.

Why an acne patch is a device, not a cosmetic

This is the part buyers skip and regret later.

A cosmetic cleans, beautifies, or alters appearance. A hydrocolloid patch that absorbs wound exudate and covers a lesion does something else — it acts as a barrier dressing. FDA's device classification for hydrocolloid wound dressings sits under 21 CFR 878.4018 (or 878.4020 for occlusive versions depending on intended use). Acne patches marketed to "heal" or "treat" pimples fit the dressing category. Market them purely as "covers and conceals" and you are, arguably, in cosmetic territory — but that distinction is a narrow line and most brands lose the argument when a retailer asks for documentation.

We've filled 2,000+ private-label runs out of Zhongshan. One pattern keeps coming back: brands that intend to sell on Amazon and Target get asked for establishment registration certificates before the purchase order is even signed. You cannot backfill that document after the fact — it takes weeks.

If your patch is strictly hydrocolloid and makes no drug claim, it is 510(k)-exempt under the Class I dressing exemption. If you add salicylic acid at a concentration above the OTC monograph threshold (0.5–2% for acne), you have crossed into drug territory and the path changes. We keep salicylic acid in stock as a cosmetic-grade BHA for these hybrid formulations — but understand that a salicylic patch claiming to treat acne is an OTC drug/device combination, not a device alone.

What your China supplier must actually provide

Ask for these documents in the RFQ stage, not after PO. Factories that hesitate here are telling you something.

• FDA establishment registration number, current year
• Device listing confirmation for the specific product code
• ISO 22716 or Cosmetics GMP certificate (cosmetics) and ISO 13485 if they claim device-grade manufacturing
• A US Agent agreement on file
• Technical file / DHF summary for the patch construction
• Biocompatibility or skin irritation test summary (usually ISO 10993-10 or HRIPT)
• Free sale certificate from the country of manufacture, if requested by your retailer

A real factory will send all seven within 48 hours. Ours go out same business day — that's the standard, not a favor.

If a supplier says "we don't need device registration because it's a cosmetic," that is your warning. They are either misinformed or selling you a product they've never exported to the US.

510(k) exemption: the determination you keep, not file

Most hydrocolloid acne patches are exempt from premarket notification. Exempt does not mean unregulated. It means you must be able to produce, on demand, a written determination that your specific device falls within the exempt classification.

We draft that determination letter with brands as part of onboarding. It runs 2–3 pages: device description, intended use, classification regulation citation, and a statement that no predicate clearance is required. Keep it in your quality file. FDA can request it during an inspection or a retailer audit.

If you are adding active ingredients beyond the OTC monograph, the analysis changes and you need a 510(k) or an NDA pathway. That is a USD 15,000–40,000 conversation, not a footnote.

Salicylic acid and the OTC monograph trap

Brands love the "salicylic acne patch" positioning. It sells. But 0.5–2% salicylic acid as an acne treatment ingredient puts you under the OTC monograph 21 CFR 333.310. Your patch is now a drug-device combination. That means:

• Drug Facts panel on the label
• Active ingredient listing and concentration
• Manufacturing under drug GMP (21 CFR 210/211), not just cosmetic GMP
• Possibly an NDA or ANDA depending on claims

Most private-label buyers do not want this burden. The workaround: market the salicylic patch as "clarifying" with cosmetic claims, exclude the Drug Facts panel, and stay cosmetic. That path works — but it locks you out of Amazon's "acne treatment" category filters, and pharmacy chains will push back.

We have shipped both versions. The cosmetic-positioned patch moves faster in DTC. The drug-positioned patch moves faster in retail pharmacy. Pick your channel first, then pick your formulation.

Certifications that matter for device-grade manufacturing

ISO 22716 covers cosmetic GMP. It is not sufficient for device claims. If your supplier is manufacturing a product classified as a device, ask for:

For hydrocolloid patches, most factories operate under cosmetic GMP and hold the device registration as a separate legal pathway. This is legally workable but gives you a thinner quality net. If you are selling into hospital or clinical channels, insist on ISO 13485 — no exceptions.

Lead time and MOQ for private-label acne patches

Real numbers from Q1 2026 production, our facility:

• MOQ: 1,000 units per SKU (10,000 for custom die-cut shapes)
• Sample lead time: 7–10 business days after brief approval
• Bulk production: 20–25 days after sample sign-off
• FOB Shenzhen per patch (5,000–10,000 units): USD 0.11–0.24 depending on material and pouch format
• FDA registration support: 15–20 business days parallel to production

You can run production and registration in parallel. Do not run them sequentially — you will lose a month.

For brands wanting to test a device path before committing to a full acne line, our hydrogel sheet mask production runs often start on the same line and serve as a lower-friction entry point. Hydrogel facial formats are unambiguously cosmetic and carry no device obligation.

Documentation timeline: a realistic 12-week plan

Week 1–2: Supplier selection and RFQ. Collect the seven documents above. Week 3: Formulation brief and sample order. Week 4: US Agent appointment; begin establishment registration. Week 5–7: Sample approval, artwork lock, label compliance review. Week 8: Registration confirmed; device listing filed. Week 9–11: Bulk production and QC. Week 12: Shipment, customs, US import entry.

The two places this slips: US Agent appointment (some brands take 3 weeks to sign a 1-page agreement) and label review (retailer feedback loops). Build 2 weeks of slack into your launch calendar.

FAQ

Q: What is the FDA device listing requirement for an acne patch private label from a China supplier?

You must register as a device establishment with FDA (foreign or domestic, USD 9,280 annual fee in 2026), list the specific product under your registration, hold a 510(k)-exempt determination on file, and ensure your China factory also holds a current establishment registration. Your supplier provides manufacturing-side registration; you provide the brand-side registration and listing.

Q: Is a hydrocolloid acne patch 510(k) exempt?

Yes, hydrocolloid acne patches marketed as barrier dressings without drug claims are generally 510(k)-exempt under Class I dressing classifications. "Exempt" means you do not file with FDA premarket; you must still document the exemption determination and keep it in your device file for inspection.

Q: Does adding salicylic acid change the FDA pathway for a China-made acne patch?

Yes. Salicylic acid at 0.5–2% for acne treatment moves the product into OTC drug territory under 21 CFR 333.310, creating a drug-device combination. You then need a Drug Facts panel and drug GMP manufacturing, not just cosmetic GMP. Many brands avoid this by positioning the patch cosmetically rather than as an acne treatment.

Q: What FDA fees should a brand budget for a private-label acne patch launch in 2026?

Expect USD 9,280 for annual establishment registration, USD 600–1,200 for a US Agent, and USD 400–2,500 for label compliance and exemption determination support. Total first-year regulatory spend typically lands between USD 10,000 and USD 13,000 before production costs.

Q: Can a China supplier sell private-label acne patches to US brands without FDA registration?

No. Any establishment manufacturing a device for US distribution must register with FDA and list products, regardless of where the facility sits. A supplier without current registration cannot legally ship a device into US commerce, and Amazon or Target will reject the listing when they request documentation.

Q: How long does FDA device registration take for an acne patch private label?

Establishment registration and product listing typically complete in 2–3 weeks once your US Agent is appointed and the factory's documentation is in hand. Budget 4–5 weeks total if you are also compiling the 510(k)-exemption determination and completing label review.